The results revealed that the DT treatment only slightly reduced the total number of CD11b myeloid cells in the tumor (Figure 3B) with decreases only in the number of F4/80+ TAMs (Figure 3C), but not in Gr-1+ granulocytes (Figure 3D). This evidence concerns the gene ITGAM and neoplasm.